Apr 28, 2026 08:00AM
Mar 18, 2026 09:00AM
Mar 18, 2026 08:15AM
Mar 11, 2026 10:00AM
Dec 1, 2025 07:01AM
Dec 1, 2025 07:00AM
Sep 2, 2025 08:00AM KALA BIO names Todd Bazemore as permanent CEO and director
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 8, 2025 08:00AM
May 14, 2025 08:00AM
Mar 31, 2025 08:00AM
Nov 12, 2024 08:00AM
Aug 6, 2024 08:00AM KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 04:05PM
Mar 29, 2024 08:00AM
Nov 13, 2023 08:00AM
Aug 4, 2023 08:00AM
May 9, 2023 08:00AM
Mar 3, 2023 08:02AM
Mar 3, 2023 08:00AM Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 3, 2023 08:00AM
Nov 8, 2022 08:00AM
Nov 8, 2022 08:00AM
Aug 11, 2022 07:00AM
Aug 11, 2022 07:00AM
May 16, 2022 07:00AM
May 16, 2022 07:00AM Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 3, 2022 08:03AM
May 3, 2022 08:00AM
May 3, 2022 08:00AM
May 1, 2022 09:00AM
May 1, 2022 09:00AM
Mar 29, 2022 07:04AM
Mar 29, 2022 07:00AM Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 29, 2022 07:00AM
Mar 8, 2022 08:10AM
Mar 8, 2022 08:00AM
Mar 8, 2022 08:00AM
Dec 15, 2021 06:25AM
Nov 18, 2021 04:01PM
Nov 18, 2021 04:01PM Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 15, 2021 08:47AM
Nov 15, 2021 08:47AM
Nov 15, 2021 08:45AM
Nov 15, 2021 08:45AM
Nov 15, 2021 08:45AM
Nov 16, 2020 07:08AM
Nov 16, 2020 07:00AM Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease
Apr 3, 2018 08:00AM

1,160,146 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All